{
  "id": 8259288,
  "title": "Biotech catalyst stocks with binary events coming up",
  "url": "https://urgent.news/2026/09/18/biotech-catalyst-stocks-with-binary-events-coming-up",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T14:32:26.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/biotech-catalyst-stocks-with-binary-events-coming-up-93CH-4907574"
  },
  "original_language": "en",
  "account": "Several biotech stocks are poised for binary events in the coming weeks, according to Investing.com. Among the potential catalysts are Arcturus Therapeutics Holdings Inc (ARCT) and MediciNova (MNOV).\n\nArcturus Therapeutics is currently trading at $17.07 per share. The company is awaiting Phase II data on OTC-deficiency later this September 2026. Additionally, ARCT is eagerly anticipating a Q4 decision on its cystic-fibrosis Phase III trial.\n\nMediciNova, on the other hand, is currently trading at $3.36 per share. The company's MN-001 is expected to report Phase II data in September 2026. Moreover, MediciNova is waiting on the COMBAT-ALS readout, which is anticipated by the end of 2026.\n\nInovio Pharmaceuticals Inc (INO) is currently trading at $1.225 per share. The company is awaiting a decision from the FDA on its PDUFA for INO-3107, which is set for October 30, 2026.\n\nLastly, Eyepoint Pharmaceuticals Inc (EYPT) is currently trading at $3.93 per share. The company is eagerly awaiting Phase III data on LUCIA, which is expected in the fourth quarter of 2026.\n\nWhile these companies present intriguing investment opportunities, it's important to note that each comes with its own set of risks. Clinical-stage biotech companies operate in a narrow window, where the potential for reward is high, but so too is the potential for significant downside if the data does not meet expectations.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}